InnoPharma Inc. Raises $8 Million in Venture Debt
Summary
Proceeds will provide additional working capital and will support the Companys ongoing development of niche generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. We remain focused and committed to delivering on our goal of providing patients and prescribers access to cost effective, safe and easy-to-use products that are, where possible, improved over currently available presentations. ""InnoPharma has a robust pipeline of unique specialty pharmaceutical products and the team has made great strides tackling many of the formulation challenges currently facing drug developers," said Jeff Chapman, senior vice president at Comerica. We are extremely pleased to provide a flexible financing solution to a company with such demonstrated talent for producing complicated drugs that service significant market needs. Target clients range from pre-revenue companies led by dedicated entrepreneurs to late-stage, proven businesses seeking more efficient growth capital.